{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:31:32Z","timestamp":1771954292800,"version":"3.50.1"},"reference-count":75,"publisher":"Bentham Science Publishers Ltd.","issue":"13","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2020,9,14]]},"abstract":"<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>Acridine is a well-known DNA intercalator and thereby gets easily inserted within\nDNA. As uncontrolled rapid cell division is one of the primary characteristics of the tumors, it is expected that\nacridine or its suitable derivatives will have preferential accumulation in the tumorous lesions. Therefore, an\nattempt was made to radiolabel an acridine derivative with <jats:sup>68<\/jats:sup>Ga and study the potential of the <jats:sup>68<\/jats:sup>Ga-acridine\ncomplex as a PET agent for tumor imaging.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>9-aminoacridine was coupled with p-NCS-benzyl-DOTA to render it suitable for labeling with <jats:sup>68<\/jats:sup>Ga.\nThe purified acridine-DOTA conjugate was radiolabeled with <jats:sup>68<\/jats:sup>Ga, eluted from a <jats:sup>68<\/jats:sup>Ge\/<jats:sup>68<\/jats:sup>Ga radionuclide generator.\nVarious radiolabeling parameters were optimized and the stability of the radiolabeled preparation was\nstudied. The biological behavior of the <jats:sup>68<\/jats:sup>Ga-acridine complex was studied both in vitro and in vivo using Raji\ncell line and fibrosarcoma tumor bearing Swiss mice, respectively.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p><jats:sup>68<\/jats:sup>Ga-acridine complex was obtained with ~100% radiochemical purity under the optimized reaction\nconditions involving incubation of 2mg\/mL of ligand at 100\u00b0C for 30 minutes. The complex maintained a radiochemical\npurity of &gt;95% in normal saline and &gt;65% in human blood serum at 3h post-incubation. In vitro cellular\nstudy showed (3.2\u00b10.1)% uptake of the radiotracer in the Raji cells. Biodistribution study revealed significant\ntumor accumulation [(11.41\u00b10.41)% injected activity in per gram] of the radiotracer within 1h postadministration\nalong with uptake in other non-target organs such as, blood, liver, GIT kidney etc.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The present study indicates the potential of <jats:sup>68<\/jats:sup>Ga-acridine as a PET agent for imaging of tumorous\nlesions. However, further detailed evaluation of the agent is warranted to explore its actual potential.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871520620666200502002609","type":"journal-article","created":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T00:26:47Z","timestamp":1588379207000},"page":"1538-1547","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Preparation and Preliminary Evaluation of 68 Ga-Acridine: An Attempt to Study the Potential of Radiolabeled DNA Intercalator as a PET Radiotracer for Tumor Imaging"],"prefix":"10.2174","volume":"20","author":[{"given":"Subhajit","family":"Ghosh","sequence":"first","affiliation":[{"name":"Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai-400085, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2877-0683","authenticated-orcid":true,"given":"Tapas","family":"Das","sequence":"additional","affiliation":[{"name":"Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai-400085, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shishu K.","family":"Suman","sequence":"additional","affiliation":[{"name":"Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai-400085, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haladhar D.","family":"Sarma","sequence":"additional","affiliation":[{"name":"Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Trombay, Mumbai-400085, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashutosh","family":"Dash","sequence":"additional","affiliation":[{"name":"Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai-400085, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65(1)","author":"Siegel, R.L.","year":"2015","unstructured":"Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics. 2015. CA Cancer J. Clin. 2015,65(1),5-29. http:\/\/dx.doi.org\/10.3322\/caac.21254 PMID: 25559415","journal-title":"CA Cancer J.Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"96.","DOI":"10.1186\/s13058-019-1168-2","volume":"21(1)","author":"Terry, M.B.","year":"2019","unstructured":"Terry, M.B.; Michels, K.B.; Brody, J.G.; Byrne,C.; Chen,S.; Jerry, D.J.; Malecki, K.M.C.; Martin, M.B.; Miller, R.L.; Neuhausen, S.L.; Silk,K.; Trentham-Dietz, A. Breast Cancer and the Environ-ment Research Program (BCERP) . Environmental exposures dur-ing windows of susceptib ility for breast cancer: A framework for prevention research. Breast Cancer Res. 2019,21(1),96. http:\/\/dx.doi.org\/10.1186\/s13058-019-1168-2 PMID: 31429809","journal-title":"Breast Cancer Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jama.2019.8430","volume":"322(7)","author":"Nelson, H.D.","year":"2019","unstructured":"Nelson, H.D.; Pappas,M.; Cantor,A.; Haney,E.; Holmes, R. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: Updated evidence report and systematic review for the US preventive services task force,J. AMA. 2019,322(7),666-685. http:\/\/dx.doi.org\/10.1001\/jama.2019.8430 PMID: 31429902","journal-title":"AMA"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1001\/jamaoncol.2019.2109","volume":"5(11)","author":"Schmitz, K.H.","year":"2019","unstructured":"Schmitz, K.H.; Troxel, A.B.; Dean, L.T.; DeMichele,A.; Brown, J.C.; Sturgeon,K.; Zhang,Z.; Evangelisti,M.; Spinelli,B.; Kallan, M.J.; Denlinger,C.; Cheville,A.; Winkels, R.M.; C hodosh,L.; Sarwer, D.B. Effect of home-based exercise and weight loss pro-grams on breast cancer-related lymphedema outcomes among overweight breast cancer survivors: The WISER survivor random-ized clinical trial,J. AMA Oncol. 2019,5(11),1605-1613. http:\/\/dx.doi.org\/10.1001\/jamaoncol.2019.2109 PMID: 31415063","journal-title":"AMA Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3322\/caac.21203","volume":"64(1)","author":"DeSantis,C.","year":"2014","unstructured":"DeSantis,C.; Ma,J.; Bryan,L.; Jemal, A. Breast cancer statistics. 2013. CA Cancer J. Clin. 2014,64(1),52-62. http:\/\/dx.doi.org\/10.3322\/caac.21203 PMID: 24114568","journal-title":"CA Cancer J.Clin"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/S1470-2045(13) 70567-9","volume":"15(7)","author":"Fan,L.","year":"2014","unstructured":"Fan,L.; Strasser-Weippl,K.; Li, J.J.; St Louis,J.; Finkelstein, D.M.; Yu, K.D.; Chen, W.Q.; Shao, Z.M.; Goss, P.E. Breast cancer in China. Lancet Oncol. 2014,15(7),e279-e289. http:\/\/dx.doi.org\/10.1016\/S1470-2045(13) 70567-9 PMID: 24872111","journal-title":"Lancet Oncol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"955","DOI":"10.4161\/cbt.10.10.13879","volume":"10(10)","author":"Malhotra, G.K.","year":"2010","unstructured":"Malhotra, G.K.; Zhao,X.; Band,H.; Band, V. Histological, mo-lecular and functional subtypes of breast cancers. Cancer Biol. Ther. 2010,10(10),955-960. http:\/\/dx.doi.org\/10.4161\/cbt.10.10.13879 PMID: 21057215","journal-title":"Cancer Biol.Ther"},{"key":"ref=8","doi-asserted-by":"publisher","author":"Yeo, S.K.","unstructured":"Yeo, S.K.; Guan, J.L. Breast cancer: Multiple subtypes within a tumor? Trends Cancer. 2017,3(11),753-760. http:\/\/dx.doi.org\/10.1016\/j.trecan.2017.09.001 PMID: 29120751","DOI":"10.1016\/j.trecan.2017.09.001"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0140-6736(16) 31891-8","volume":"389(10074)","author":"Harbeck,N.","year":"2017","unstructured":"Harbeck,N.; Gnant, M. Breast cancer. Lancet. 2017,389(10074),1134-1150. http :\/\/dx.doi.org\/10.1016\/S0140-6736(16) 31891-8 PMID: 27865536","journal-title":"Lancet"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1158\/0008-5472.CAN-16-2574","volume":"77(13)","author":"Holm,J.","year":"2017","unstructured":"Holm,J.; Eriksson,L.; Ploner,A.; Eriksson,M.; Rantalainen,M.; Li,J.; Hall,P.; Czene, K. Assessment of breast cancer risk factors reveals subtype heterogeneity. Cancer Res. 2017,77(13),3708-3717. http :\/\/dx.doi.org\/10.1158\/0008-5472.CAN-16-2574 PMID: 28512241","journal-title":"Cancer Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2350.","DOI":"10.1016\/S0140-6736(17) 31662-8","volume":"389(10087)","author":"The,L","year":"2017","unstructured":"The.; L. The Lancet. Breast cancer targeted therapy: Successes and challenges. Lancet. 2017,389(10087),2350. http:\/\/dx.doi.org\/10.1016\/S0140-6736(17) 31662-8 PMID: 28635596","journal-title":"Lancet"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijrobp.2017.08.025","volume":"100(1)","author":"Horton, J.K.","year":"2018","unstructured":"Horton, J.K.; Jagsi,R.; Woodward, W.A.; Ho, A. Breast cancer biology: Clinical implications for breast radiation therapy. Int, J. Radiat. Oncol. Biol. Phys. 2018,100(1),23-37. http:\/\/dx.doi.org\/10.1016\/j.ijrobp.2017.08.025 PMID: 29254776","journal-title":"Int, J.Radiat.Oncol.Biol.Phys"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/jnci\/dji021","volume":"97(3)","author":"Mauri,D.","year":"2005","unstructured":"Mauri,D.; Pavlidis,N.; Ioannidis, J.P. Neoadjuvant versus adju-vant systemic treatment in breast cancer: A meta-analysis, J. Natl. Cancer Inst. 2005,97(3),188-194. http:\/\/dx.doi.org\/10.1093\/jnci\/dji021 PMID: 15687361","journal-title":"Natl.Cancer Inst"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"61S","DOI":"10.2967\/jnumed.116.186783","volume":"58((Suppl 2) )","author":"Fani,M.","year":"2017","unstructured":"Fani,M.; Nicolas, G.P.; Wild, D. Somatostatin receptor antagonists for imaging and therapy, J. Nuclear Med. 2017,58((Suppl 2) ),61S-66S","journal-title":"Nuclear Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s00259-015-3114-6","volume":"42(13)","author":"Traub-Weidinger,T.","year":"2015","unstructured":"Traub-Weidinger,T.; Putzer,D.; von Guggenberg,E.; Dobrozem-sky,G.; Nilica,B.; Kendler,D.; Bale,R.; Virgolini, I.J. Multi-parametric PET imaging in thyroid malignancy characterizing tu-mour heterogeneity: Somatostatin receptors and glucose metabo-lism. Eur, J. Nucl. Med. Mol. Imaging. 2015,42(13),1995-2001. http:\/\/dx.doi.org\/10.1007\/s00259-015-3114-6 PMID: 26173620","journal-title":"Eur, J.Nucl.Med.Mol.Imaging"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"900","DOI":"10.2967\/jnumed.117.202010","volume":"59(6)","author":"Ulaner, G.A.","year":"2018","unstructured":"Ulaner, G.A.; Lyashchenko, S.K.; Riedl,C.; Ruan,S.; Zanzonico, P.B.; Lake,D.; Jhaveri,K.; Zeglis,B.; Lewis, J.S.; O'Donoghue, J.A. First-in-Human human epidermal growth factor receptor 2-targeted imaging using (89) Zr-Pertuzumab PET\/CT: Dosimetry and clinical application in patients with breast cancer, J. Nuclear Med. 2018,59(6),900-906","journal-title":"Nuclear Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ctrv.2018.04.016","volume":"67","author":"Pond\u00e9, N.","year":"2018","unstructured":"Pond\u00e9, N.; Brand\u00e3o,M.; El-Hachem,G.; Werbrouck,E.; Piccart, M. Treatment of advanced HER2-positive breast cancer: 2 018 and beyond. Cancer Treat. Rev. 2018,67,10-20. http:\/\/dx.doi.org\/10.1016\/j.ctrv.2018.04.016 PMID: 29751334","journal-title":"Cancer Treat.Rev"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1038\/sj.onc.1210374","volume":"26(25)","author":"Takeda,K.","year":"2007","unstructured":"Takeda,K.; Stagg,J.; Yagita,H.; Okumura,K.; Smyth, M.J. Tar-geting death-inducing receptors in cancer therapy. Oncogene. 2007,26(25),3745-3757. http:\/\/dx.doi.org\/10.1038\/sj.onc.1210374 PMID: 17530027","journal-title":"Oncogene"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.4161\/cc.7.11.5975","volume":"7(11)","author":"Finnberg,N.","year":"2008","unstructured":"Finnberg,N.; El-Deiry, W.S. TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle. 2008,7(11),1525-1528. http:\/\/dx.doi.org\/10.4161\/cc.7.11.5975 PMID: 18469516","journal-title":"Cell Cycle"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"90.","DOI":"10.1186\/s12929-017-0398-9","volume":"24(1)","author":"Mart\u00ednez-Reza,I.","year":"2017","unstructured":"Mart\u00ednez-Reza,I.; D\u00edaz,L.; Garc\u00eda-Becerra, R. Preclinical and clinical aspects of TNF-a and its receptors TNFR1 and TNFR2 in breast cancer, J. Biomed. Sci. 2017,24(1),90. http:\/\/dx.doi.org\/10.1186\/s12929-017-0398-9 PMID: 29202842","journal-title":"Biomed.Sci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"13030","DOI":"10.1073\/pnas.1709119114","volume":"114(49)","author":"Basudhar,D.","year":"2017","unstructured":"Basudhar,D.; Glynn, S.A.; Greer,M.; Somasundaram,V.; No, J.H.; Scheiblin, D.A.; Garrido,P.; Heinz, W.F.; Ryan, A.E.; Weiss, J.M.; Cheng, R.Y.S.; Ridnour, L.A.; Locke-tt, S.J.; McVicar, D.W.; Ambs,S.; Wink, D.A. Coexpression of NOS2 and COX2 acceler-ates tumor growth and reduces survival in estrogen receptor-negative breast cancer. Proc. Natl. Acad. Sci. USA. 2017,114(49),13030-13035. http:\/\/dx.doi.org\/10.1073\/pnas.1709119114 PMID: 29087320","journal-title":"Proc.Natl.Acad.Sci.USA"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"29.","DOI":"10.1186\/1475-2867-12-29","volume":"12(1)","author":"Labovsky,V.","year":"2012","unstructured":"Labovsky,V.; Vallone, V.B.; Martinez, L.M.; Otaegui,J.; Chasseing, N.A. Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines. Cancer Cell Int. 2012,12(1),29. http:\/\/dx.doi.org\/10.1186\/1475-2867-12-29 PMID: 22709548","journal-title":"Cancer Cell Int"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/CAD.0b013e32830b5894","volume":"19(8)","author":"Yeruva,L.","year":"2008","unstructured":"Yeruva,L.; Elegbede, J.A.; Carper, S.W. Methyl jasmonate de-creases membrane fluidity and induces apoptosis through tumor necrosis factor receptor 1 in breast cancer cells. Anticancer Drugs. 2008,19(8),766-776. http:\/\/dx.doi.org\/10.1097\/CAD.0b013e32830b5894 PMID: 18690087","journal-title":"Anticancer Drugs"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.yexcr.2007.10.005","volume":"314(3)","author":"Rivas, M.A.","year":"2008","unstructured":"Rivas, M.A.; Carnevale, R.P.; Proietti, C.J.; Rosemblit,C.; Be-guelin,W.; Salatino,M.; Charreau, E.H.; Frahm,I.; Sapia,S.; Brouckaert,P.; Elizalde, P.V.; Schillaci, R. TNF alpha acting on TNFR1 promotes breast cancer growth via p42\/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. Exp. Cell Res. 2008,314(3),509-529. http:\/\/dx.doi.org\/10.1016\/j.yexcr.2007.10.005 PMID: 18061162","journal-title":"Exp.Cell Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cytogfr.2014.03.004","volume":"25(3)","author":"Puim\u00e8ge,L.","year":"2014","unstructured":"Puim\u00e8ge,L.; Libert,C.; Van Hauwermeiren, F. Regulation and dysregulation of tumor necrosis factor receptor-1. Cytokine Growth Factor Rev. 2014,25(3),285-300. http:\/\/dx.doi.org\/10.1016\/j.cytogfr.2014.03.004 PMID: 24746195","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc2628","volume":"9(5)","author":"Balkwill,F","year":"2009","unstructured":"Balkwill.; F. Tumour necrosis factor and cancer. Nat. Rev. Cancer. 2009,9(5),361-371. http:\/\/dx.doi.org\/10.1038\/nrc2628 PMID: 19343034","journal-title":"Nat.Rev.Cancer"},{"key":"ref=27","author":"Xiao, Z.X.","unstructured":"Xiao, Z.X.; Willette-Brown,J.; Hu, Y.L.; Xi, S.C. TNFR1 is indis-pensable in the development of spontaneous lung squamous cell carcinomas. Cancer Res. 2014,74(19)","journal-title":"Cancer Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"4944.","DOI":"10.1038\/ncomms5944","volume":"5","author":"Ji,H.","year":"2014","unstructured":"Ji,H.; Cao,R.; Yang,Y.; Zhang,Y.; Iwamoto,H.; Lim,S.; Naka-mura,M.; Andersson,P.; Wang,J.; Sun,Y.; Dissing,S.; He,X.; Yang,X.; Cao, Y. TNFR1 mediates TNF-a-induced tumour lym-phangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling. Nat. Commun. 2014,5,4944. http:\/\/dx.doi.org\/10.1038\/ncomms5944 PMID: 25229256","journal-title":"Nat.Commun"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00726-017-2526-y","volume":"50(3-4)","author":"Fu,H.","year":"2018","unstructured":"Fu,H.; Wu,H.; Zhang,X.; Huang,J.; He,X.; Chen,L.; Guo,W.; Guo,X.; Hao,B.; Li, Y. Pre-clinical study of a TNFR1-targeted 18F probe for PET imaging of breast cancer. Amino Acids. 2018,50(3-4),409-419. http:\/\/dx.doi.org\/10.1007\/s00726-017-2526-y PMID: 29243062","journal-title":"Amino Acids"},{"key":"ref=30","author":"Eliceiri, B.P.","unstructured":"Eliceiri, B.P.; Cheresh, D.A. Role of alpha v integrins during angi-ogenesis. Cancer J. 2000,6(Suppl. 3),S245-S249. PMID: 10874494","journal-title":"Cancer J"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10(1)","author":"Desgrosellier, J.S.","year":"2010","unstructured":"Desgrosellier, J.S.; Cheresh, D.A. Integrins in cancer: Biological implications and therapeutic opportunities. Nat. Rev. Cancer. 2010,10(1),9-22. http:\/\/dx.doi.org\/10.1038\/nrc2748 PMID: 20029421","journal-title":"Nat.Rev.Cancer"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.canlet.2017.06.012","volume":"403","author":"Niu,J.","year":"2017","unstructured":"Niu,J.; Li, Z. The roles of integrin a v\u00df6 in cancer. Cancer Lett. 2017,403,128-137. http:\/\/dx.doi.org\/10.1016\/j.canlet.2017.06.012 PMID: 28634043","journal-title":"Cancer Lett"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/nrm2871","volume":"11(4)","author":"Shattil, S.J.","year":"2010","unstructured":"Shattil, S.J.; Kim,C.; Ginsberg, M.H. The final steps of integrin activation: the end game. Nat. Rev. Mol. Cell Biol. 2010,11(4),288-300. http:\/\/dx.doi.org\/10.1038\/nrm2871 PMID: 20308986","journal-title":"Nat.Rev.Mol.Cell Biol"},{"key":"ref=34","first-page":"5139","volume":"62(18)","author":"Zitzmann,S.","year":"2002","unstructured":"Zitzmann,S.; Ehemann,V.; Schwab, M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res. 2002,62(18),5139-5143. PMID: 12234975","journal-title":"Cancer Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1021\/ml500135t","volume":"5(9)","author":"Park, J.A.","year":"2014","unstructured":"Park, J.A.; Lee, Y.J.; Lee, J.W.; Lee, K.C.; An, G.I.; Kim, K.M.; Kim, B.I.; Kim, T.J.; Kim, J.Y. Cyclic RGD Peptides Incorporating Cycloalkanes: Synthesis and Evaluation as PET Radiotracers for Tumor Imaging. ACS Med. Chem. Lett. 2014,5(9),979-982. http:\/\/dx.doi.org\/10.1021\/ml500135t PMID: 25221652","journal-title":"ACS Med.Chem.Lett"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jcis.2014.07.032","volume":"433","author":"Tsiapa,I.","year":"2014","unstructured":"Tsiapa,I.; Efthimiadou, E.K.; Fragogeorgi,E.; Loudos,G.; Var-varigou, A.D.; Bouziotis,P.; Kordas, G.C.; Mihailidis,D.; Niki-foridis, G.C.; Xanthopoulos,S.; Psimadas,D.; Paravatou-Petsotas,M.; Palamaris,L.; Hazle, J.D.; Kagadis, G.C. (99m) Tc-labeled aminosilane-coated iron oxide nanoparticles for molecular imaging of a?\u00df3-mediated tumor expression and feasibility for hyperthermia treatment, J. Colloid Interface Sci. 2014,433,163-175. http:\/\/dx.doi.org\/10.1016\/j.jcis.2014.07.032 PMID: 25128864","journal-title":"Colloid Interface Sci"},{"key":"ref=37","author":"Haubner,R.","unstructured":"Haubner,R.; Beer, A.J.; Wang,H.; Chen, X. Positron emission tomography tracers for imaging angiogenesis. Eur, J. Nucl. Med. Mol. Imaging. 2010,37(1) (Suppl. 1),S86-S103. http:\/\/dx.doi.org\/10.1007\/s00259-010-1503-4 PMID: 20559632","journal-title":"Eur, J.Nucl.Med.Mol.Imaging"},{"key":"ref=38","author":"Yu,C.","unstructured":"Yu,C.; Pan,D.; Mi,B.; Xu,Y.; Lang,L.; Niu,G.; Yang,M.; Wan,W.; Chen, X. (18) F-Alfatide II PET\/CT in healthy human. unteers and patients with brain metastases. Eur, J. Nucl. Med. Mol. Imag-ing. 2015,42(13),2021-2028. http:\/\/dx.doi.org\/10.1007\/s00259-015-3118-2 PMID: 26121930","journal-title":"Eur, J. Nucl. Med. Mol. Imag-ing."},{"key":"ref=39","author":"Zhang,H.","unstructured":"Zhang,H.; Liu,N.; Gao,S.; Hu,X.; Zhao,W.; Tao,R.; Chen,Z.; Zheng,J.; Sun,X.; Xu,L.; Li,W.; Yu,J.; Yuan, S. Can an (1) (8) F-ALF-NOTA-PRGD2 PET\/CT scan predict treatment sensitivity to concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma? Journal Nuclear Med. 2016,57(4),524-9","journal-title":"Journal Nuclear Med."},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1148\/radiol.2016150813","volume":"281(3)","author":"Jin,X.","year":"2016","unstructured":"Jin,X.; Liang,N.; Wang,M.; Meng,Y.; Jia,B.; Shi,X.; Li,S.; Luo,J.; Luo,Y.; Cui,Q.; Zheng,K.; Liu,Z.; Shi,J.; Li,F.; Wang,F.; Zhu, Z. Integrin Imaging with 99mTc-3PRGD2 SPECT\/CT shows high specificity in the diagnosis of lymph node metastasis from non-small cell lung cancer. Radiology. 2016,281(3),958-966. http:\/\/dx.doi.org\/10.1148\/radiol.2016150813 PMID: 27479638","journal-title":"Radiology"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s00259-016-3396-3","volume":"43(11)","author":"Haubner,R.","year":"2016","unstructured":"Haubner,R.; Finkenstedt,A.; Stegmayr,A.; Rangger,C.; Decristo-foro,C.; Zoller,H.; Virgolini, I.J. [(68) Ga]NODAGA-RGD-Metabolic stability, biodistribution, and dosimetry data from pa-tients with hepatocellular carcinoma and liver cirrhosis. Eur, J. Nucl. Med. Mol. Imaging. 2016,43(11),2005-2013. http:\/\/dx.doi.org\/10.1007\/s00259-016-3396-3 PMID: 27164900","journal-title":"Eur, J.Nucl.Med.Mol.Imaging"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s00259-016-3345-1","volume":"43(9)","author":"Chen, S.H.","year":"2016","unstructured":"Chen, S.H.; Wang, H.M.; Lin, C.Y.; Chang, J.T.; Hsieh, C.H.; Liao, C.T.; Kang, C.J.; Yang, L.Y.; Yen, T.C. RGD-K5 PET\/CT in patients with advanced head and neck cancer treated with concur-rent chemoradiotherapy: Results from a pilot study. Eur, J. Nucl. Med. Mol. Imaging. 2016,43(9),1621-1629. http:\/\/dx.doi.org\/10.1007\/s00259-016-3345-1 PMID: 26922351","journal-title":"Eur, J.Nucl.Med.Mol.Imaging"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2967\/jnumed.107.049452","volume":"49(6)","author":"Kenny, L.M.","year":"2008","unstructured":"Kenny, L.M.; Coombes, R.C.; Oulie,I.; Contractor, K.B.; M iller,M.; Spinks, T.J.; McParland,B.; Cohen, P.S.; Hui, A.M.; Palmieri,C.; Osman,S.; Glaser,M.; Turton,D.; Al-Nahhas,A.; Aboagye, E.O. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD)  peptide radioligand 18F-AH111585 in breast cancer patients. Jour-nal of Nuclear Med. 2008,49(6),879-86","journal-title":"Jour-nal of Nuclear Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.7150\/thno.12938","volume":"5(10)","author":"Mi,B.","year":"2015","unstructured":"Mi,B.; Yu,C.; Pan,D.; Yang,M.; Wan,W.; Niu,G.; Chen, X. Pilot prospective evaluation of pilot prospective evaluation of (18) F-Alfatide II for detection of skeletal metastases. Theranostics. 2015,5(10),1115-1121. http:\/\/dx.doi.org\/10.7150\/thno.12938 PMID: 26199649","journal-title":"Theranostics"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/jlcr","volume":"58(7)","author":"Yu, H.M.","year":"2015","unstructured":"Yu, H.M.; Chen, J.H.; Lin, K.L.; Lin, W.J. Synthesis of (68) Ga-labeled NOTA-RGD-GE11 heterodimeric peptide for dual integrin and epidermal growth factor receptor-targeted tumor imaging, J. Labelled Comp. Radiopharm. 2015,58(7),299-303. http:\/\/dx.doi.org\/10.1002\/jlcr. 3296 PMID: 25997858","journal-title":"Labelled Comp.Radiopharm"},{"key":"ref=46","author":"AL-Nahhas,A.","unstructured":"AL-Nahhas,A.; Fanti, S. Radiolabelled peptides in diagnosis and therapy: an introduction. Eur, J. Nucl. Med. Mol. Imaging. 2012,39(Suppl. 1),S1-S3. http:\/\/dx.doi.org\/10.1007\/s00259-012-2064-5 PMID: 22388632","journal-title":"Eur, J.Nucl.Med.Mol.Imaging"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1080\/19420862.2016.1255389","volume":"9(1)","author":"Lam,K.","year":"2017","unstructured":"Lam,K.; Chan,C.; Reilly, R.M. Development and preclinical stud-ies of 64Cu-NOTA-pertuzumab F(ab\u2019)  2 for imaging changes in tu-mor HER2 expression associated with response to trastuzumab by PET\/CT. MAbs. 2017,9(1),154-164. http:\/\/dx.doi.org\/10.1080\/19420862.2016.1255389 PMID: 27813707","journal-title":"MAbs"},{"key":"ref=48","author":"Adumeau,P.","unstructured":"Adumeau,P.; Sharma, S.K.; Brent,C.; Zeglis, B.M. Site-specifically labeled immunoconjugates for molecular imaging--Part. 2: Peptide Tags and Unnatural Amino Acids. Mol. Imaging nd Biol. 2016,18(2),153-65","journal-title":"Mol. Imaging nd Biol."},{"key":"ref=49","first-page":"88","volume":"48(1)","author":"de Visser,M.","year":"2007","unstructured":"de Visser,M.; van Weerden, W.M.; de Ridder, C.M.; Reneman,S.; Melis,M.; Krenning, E.P.; de Jong, M. Androgen-dependent expression of the gastrin-releasing peptide receptor in human pros-tate tumor xenografts, J. Nuclear Med. 2007,48(1),88-93","journal-title":"Nuclear Med"},{"key":"ref=50","first-page":"1295","volume":"5(4)","author":"Norton, K.A.","year":"2015","unstructured":"Norton, K.A.; Popel, A.S.; Pandey, N.B. Heterogeneity of chemokine cell-surface receptor expression in triple-negative breast cancer. Am, J. Cancer Res. 2015,5(4),1295-1307. PMID: 26101698","journal-title":"Am, J.Cancer Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366(10)","author":"Gerlinger,M.","year":"2012","unstructured":"Gerlinger,M.; Rowan, A.J.; Horswell,S.; Math,M.; Larkin,J.; Endesfelder,D.; Gronroos,E.; Martinez,P.; Matthews,N.; Stewart,A.; Tarpey,P.; Varela,I.; Phillimore,B.; Begum,S.; McDonald, N.Q.; Butler,A.; Jones,D.; Raine,K.; Latimer,C.; Santos, C.R.; Nohadani,M.; Eklund, A.C.; Spencer-Dene,B.; Clark,G.; Picker-ing,L.; Stamp,G.; Gore,M.; Szallasi,Z.; Downward,J.; Futreal, P.A.; Swanton, C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N. Engl, J. Med. 2012,366(10),883-892. http:\/\/dx.doi.org\/10.1056\/NEJMoa1113205 PMID: 22397650","journal-title":"Engl, J.Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.nucmedbio.2005.05.005","volume":"32(7)","author":"Smith, C.J.","year":"2005","unstructured":"Smith, C.J.; Volkert, W.A.; Hoffman, T.J. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily sub-types. Nucl. Med. Biol. 2005,32(7),733-740. http:\/\/dx.doi.org\/10.1016\/j.nucmedbio.2005.05.005 PMID: 16243649","journal-title":"Nucl.Med.Biol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s11307-014-0761-0","volume":"16(6)","author":"Wu,H.","year":"2014","unstructured":"Wu,H.; Chen,H.; Pan,D.; Ma,Y.; Liang,S.; Wan,Y.; Fang, Y. Imaging integrin a v\u00df3 and NRP-1 positive gliomas with a novel fluorine-18 labeled RGD-ATWLPPR heterodimeric peptide probe. Mol. Imaging Biol. 2014,16(6),781-792. http:\/\/dx.doi.org\/10.1007\/s11307-014-0761-0 PMID: 25001194","journal-title":"Mol.Imaging Biol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.nucmedbio.2013.11.006","volume":"41(2)","author":"Durkan,K.","year":"2014","unstructured":"Durkan,K.; Jiang,Z.; Rold, T.L.; Sieckman, G.L.; Hoffman, T.J.; Bandari, R.P.; Szczodroski, A.F.; Liu,L.; Miao,Y.; Reynolds, T.S.; Smith, C.J. A heterodimeric [RGD-Glu-[(64) Cu-NO2A]-6-Ahx-RM2] a v\u00df3\/GRPr-targeting antagonist radiotracer for PET im-aging of prostate tumors. Nucl. Med. Biol. 2014,41(2),133-139. http:\/\/dx.doi.org\/10.1016\/j.nucmedbio.2013.11.006 PMID: 24480266","journal-title":"Nucl.Med.Biol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/MNM.0b013e328362d2b6","volume":"34(9)","author":"Jiang,L.","year":"2013","unstructured":"Jiang,L.; Miao,Z.; Liu,H.; Ren,G.; Bao,A.; Cutler, C.S.; Shi,H.; Cheng, Z. 177Lu-labeled RGD-BBN heterodimeric peptide for tar-geting prostate carcinoma. Nucl. Med. Commun. 2013,34(9),909-914. http :\/\/dx.doi.org\/10.1097\/MNM.0b013e328362d2b6 PMID: 23708872","journal-title":"Nucl.Med.Commun"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2967\/jnumed.117.199877","volume":"59(3)","author":"Ehlerding, E.B.","year":"2018","unstructured":"Ehlerding, E.B.; Sun,L.; Lan,X.; Zeng,D.; Cai, W. Dual-targeted molecular imaging of cancer, J. Nuclear Med. 2018,59(3),390-395","journal-title":"Nuclear Med"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1021\/bc9000245","volume":"20(5)","author":"Liu,Z.","year":"2009","unstructured":"Liu,Z.; Yan,Y.; Liu,S.; Wang,F.; Chen, X. (18) F, (64) Cu, and (68) Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug. Chem. 2009,20(5),1016-1025. http:\/\/dx.doi.org\/10.1021\/bc9000245 PMID: 20540537","journal-title":"Bioconjug.Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00726-010-0546-y","volume":"41(5)","author":"Yan,Y.","year":"2011","unstructured":"Yan,Y.; Chen, X. Peptide heterodimers for molecular imaging. Amino Acids. 2011,41(5),1081-1092. http:\/\/dx.doi.org\/10.1007\/s00726-010-0546-y PMID: 20232091","journal-title":"Amino Acids"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.nucmedbio.2018.11.003","volume":"68-69","author":"Chen, C.J.","year":"2019","unstructured":"Chen, C.J.; Chan, C.H.; Lin, K.L.; Chen, J.H.; Tseng, C.H.; Wang, P.Y.; Chien, C.Y.; Yu, H.M.; Lin, W.J. 68Ga-labelled NOTA-RGD-GE11 peptide for dual integrin and EGFR-targeted tumour imag-ing. Nucl. Med. Biol. 2019,68-69,22-30. http:\/\/dx.doi.org\/10.1016\/j.nucmedbio.2018.11.003 PMID: 30578136","journal-title":"Nucl.Med.Biol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jlcr","volume":"57(11)","author":"Ma,Y.","year":"2014","unstructured":"Ma,Y.; Liang,S.; Guo,J.; Guo,R.; Wang, H. (18) F labeled RGD-A7R peptide for dual integrin and VEGF-targeted tumor imaging in mice bearing U87MG tumors, J. Labelled Comp. Radiopharm. 2014,57(11),627-631. http:\/\/dx.doi.org\/10.1002\/jlcr. 3222 PMID: 25294311","journal-title":"Labelled Comp.Radiopharm"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"164.","DOI":"10.1159\/000488340","volume":"41(4)","author":"Marm\u00e9.","year":"2018","unstructured":"Marm\u00e9.; D. Tumor angiogenesis: A key target for cancer therapy. Oncol. Res. Treat. 2018,41(4),164. http:\/\/dx.doi.org\/10.1159\/000488340 PMID: 29587285","journal-title":"Oncol.Res.Treat"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"22.","DOI":"10.1186\/s12943-018-0766-4","volume":"17(1)","author":"Wang,Y.","year":"2018","unstructured":"Wang,Y.; Wang,L.; Chen,C.; Chu, X. New insights into the regu-latory role of microRNA in tumor angiogenesis and clinical impli-cations. Mol. Cancer. 2018,17(1),22. http:\/\/dx.doi.org\/10.1186\/s12943-018-0766-4 PMID: 29415727","journal-title":"Mol.Cancer"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"E268.","DOI":"10.3390\/cancers10080268","volume":"10(8)","author":"Pirola,L.","year":"2018","unstructured":"Pirola,L.; Ciesielski,O.; Balcerczyk, A. The methylation status of the epigenome: Its emerging role in the regulation of tumor angio-genesis and tumor growth, and potential for drug targeting. Can-cers (Basel). 2018,10(8),E268. http:\/\/dx.doi.org\/10.3390\/cancers10080268 PMID: 30103412","journal-title":"Can-cers (Basel)"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"69.","DOI":"10.3389\/fonc.2014.00069","volume":"4","author":"Stockmann,C.","year":"2014","unstructured":"Stockmann,C.; Schadendorf,D.; Klose,R.; Helfrich, I. The impact of the immune system on tumor: angiogenesis and vascular remod-eling. Front. Oncol. 2014,4,69. http:\/\/dx.doi.org\/10.3389\/fonc.2014.00069 PMID: 24782982","journal-title":"Front.Oncol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1074\/jbc.M111.269811","volume":"287(3)","author":"Lonsdorf, A.S.","year":"2012","unstructured":"Lonsdorf, A.S.; Kr\u00e4mer, B.F.; Fahrleitner,M.; Sch\u00f6nberger,T.; Gnerlich,S.; Ring,S.; Gehring,S.; Schneider, S.W.; Kruhlak, M.J.; Meuth, S.G.; Nieswandt,B.; Gawaz,M.; Enk, A.H.; Langer, H.F. Engagement of aIIb\u00df3 (GPIIb\/IIIa)  with a ?\u00df3 integrin mediates in-teraction of melanoma cells with platelets: A connection to hema-togenous metastasis, J. Biol. Chem. 2012,287(3),2168-2178. http:\/\/dx.doi.org\/10.1074\/jbc.M111.269811 PMID: 22102277","journal-title":"Biol.Chem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"78","DOI":"10.7150\/thno.13242","volume":"6(1)","author":"Chen,H.","year":"2016","unstructured":"Chen,H.; Niu,G.; Wu,H.; Chen, X. Clinical application of radio-labeled RGD peptides for PET imaging of integrin a v\u00df3. Theranos-tics. 2016,6(1),78-92. http:\/\/dx.doi.org\/10.7150\/thno.13242 PMID: 26722375","journal-title":"Theranos-tics"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/jnci\/djt263","volume":"105(20)","author":"Shin, D.H.","year":"2013","unstructured":"Shin, D.H.; Lee, H.J.; Min, H.Y.; Choi, S.P.; Lee, M.S.; Lee, J.W.; Johnson, F.M.; Mehta,K.; Lippman, S.M.; Glisson, B.S.; Lee, H.Y. Combating resistance to anti-IGFR antibody by targeting the in-tegrin \u00df3-Src pathway, J. Natl. Cancer Inst. 2013,105(20),1558-1570. http:\/\/dx.doi.org\/10.1093\/jnci\/djt263 PMID: 24092920","journal-title":"Natl.Cancer Inst"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1007\/s00259-011-1847-4","volume":"38(9)","author":"Liu,S.","year":"2011","unstructured":"Liu,S.; Liu,H.; Jiang,H.; Xu,Y.; Zhang,H.; Cheng, Z. One-step radiosynthesis of 18F-AlF-NOTA-RGD 2 for tumor angiogenesis PET imaging. Eur, J. Nucl. Med. Mol. Imaging. 2011,38(9),1732-1741. http:\/\/dx.doi.org\/10.1007\/s00259-011-1847-4 PMID: 21617974","journal-title":"Eur, J.Nucl.Med.Mol.Imaging"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"e0141668.","DOI":"10.1371\/journal.pone.0141668","volume":"10(11)","author":"Liu,Q.","year":"2015","unstructured":"Liu,Q.; Pan,D.; Cheng,C.; Zhang,D.; Zhang,A.; Wang,L.; Ji-ang,H.; Wang,T.; Liu,H.; Xu,Y.; Yang,R.; Chen,F.; Yang,M.; Zuo, C. Development of a novel PET tracer [18F]AlF-NOTA-C6 targeting MMP2 for tumor imaging. PLoS One. 2015,10(11),e0141668. http:\/\/dx.doi.org\/10.1371\/journal.pone.0141668 PMID: 26540114","journal-title":"PLoS One"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"36.","DOI":"10.1186\/2191-219X-3-36","volume":"3(1)","author":"McBride, W.J.","year":"2013","unstructured":"McBride, W.J.; Sharkey, R.M.; Goldenberg, D.M. Radiofluorina-tion using aluminum-fluoride (Al18F) . EJNMMI Res. 2013,3(1),36. http:\/\/dx.doi.org\/10.1186\/2191-219X-3-36 PMID: 23651690","journal-title":"EJNMMI Res"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2967\/jnumed.108.060418","volume":"50(6)","author":"McBride, W.J.","year":"2009","unstructured":"McBride, W.J.; Sharkey, R.M.; Karacay,H.; D'Souza, C.A.; Rossi, E.A.; Laverman,P.; Chang, C.H.; Boerman, O.C.; Goldenberg, D.M. A novel method of 18F radiolabeling for PET. J. Nuclear Med. 2009,50(6),991-8","journal-title":"J..Nuclear Med"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3109\/1061186X.2015.1020808","volume":"23(9)","author":"Xu,Q.","year":"2015","unstructured":"Xu,Q.; Zhu,C.; Xu,Y.; Pan,D.; Liu,P.; Yang,R.; Wang,L.; Chen,F.; Sun,X.; Luo,S.; Yang, M. Preliminary evaluation of [18F]AlF-NOTA-MAL-Cys39-exendin-4 in insulinoma with PET. J. Drug Target. 2015,23(9),813-820. http:\/\/dx.doi.org\/10.3109\/1061186X.2015.1020808 PMID: 25758750","journal-title":"J.Drug Target"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.7150\/thno.22601","volume":"8(4)","author":"Zhang,J.","year":"2018","unstructured":"Zhang,J.; Mao,F.; Niu,G.; Peng,L.; Lang,L.; Li,F.; Ying,H.; Wu,H.; Pan,B.; Zhu,Z.; Chen, X. 68Ga-BBN-RGD PET\/CT for GRPR and integrin a v\u00df3 imaging in patients with breast cancer. Theranostics. 2018,8(4),1121-1130. http:\/\/dx.doi.org\/10.7150\/thno.22601 PMID: 29464003","journal-title":"Theranostics"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2967\/jnumed.116.177048","volume":"58(2)","author":"Zhang,J.","year":"2017","unstructured":"Zhang,J.; Niu,G.; Lang,L.; Li,F.; Fan,X.; Yan,X.; Yao,S.; Yan,W.; Huo,L.; Chen,L.; Li,Z.; Zhu,Z.; Chen, X. Clinical translation of a dual integrin alphavbeta3-and gastrin-releasing peptide recep-tor-targeting PET radiotracer, 68Ga-BBN-RGD. J. Nuclear Med. 2017,58(2),228-234","journal-title":"J..Nuclear Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1021\/acs.bioconjchem.8b00113","volume":"29(5)","author":"Lucente,E.","year":"2018","unstructured":"Lucente,E.; Liu,H.; Liu,Y.; Hu,X.; Lacivita,E.; Leopoldo,M.; Cheng, Z. Novel 64Cu labeled RGD 2-BBN heterotrimers for PET imaging of prostate cancer. Bioconjug. Chem. 2018,29(5),1595-1604. http :\/\/dx.doi.org\/10.1021\/acs.bioconjchem.8b00113 PMID: 29587479","journal-title":"Bioconjug.Chem"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/181559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T19:32:24Z","timestamp":1602358344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/181559\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":75,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,9,14]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871520620666200502002609","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,14]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}